Endo Divests International Pharmaceuticals Business
Deal News | Mar 11, 2025 | PR Newswire Cision Endo, Inc.
Endo, Inc. has announced a definitive agreement to sell its International Pharmaceuticals business, operated primarily through Paladin Pharma Inc. in Canada, to Knight Therapeutics Inc. The transaction is worth up to $99 million, with an upfront cash payment of $84 million and an additional $15 million contingent upon milestone achievements. Knight Therapeutics, a company focused on commercializing innovative pharmaceuticals in Canada and Latin America, is considered the right fit for Paladin's future. The divestiture aligns with Endo's strategic transformation to focus on its core assets. The transaction's completion is subject to regulatory conditions, including anti-trust clearance in Canada, and is expected by mid-2025.
Sectors
- Pharmaceuticals
- Healthcare
Geography
- United States – Endo, Inc. is based in Malvern, Pennsylvania, indicating significant operations in the United States.
- Canada – Paladin Pharma Inc., the company being divested, and the purchasing company Knight Therapeutics, operate mainly in Canada.
- Latin America – Knight Therapeutics has a focus on commercializing products in Latin America, relevant to its business operations.
Industry
- Pharmaceuticals – This industry pertains to the development and commercialization of medications and therapeutic products, relevant here due to the involved companies focusing on these activities.
- Healthcare – Healthcare industry encompasses the maintenance and improvement of health, involving companies like Endo and Knight Therapeutics which focus on pharmaceutical products.
Financials
- $84 million – The upfront cash payment from Knight Therapeutics to Endo for the acquisition.
- $15 million – Potential future payments contingent upon select milestones in the transaction.
- $99 million – Total consideration for the transaction between Endo and Knight Therapeutics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Endo, Inc. | Selling Company | Company | A diversified pharmaceutical company transforming insights into therapeutic products. |
| Paladin Pharma Inc. | Target company | Company | A Canada-based specialty pharmaceutical company, part of Endo's International Pharmaceuticals segment. |
| Knight Therapeutics Inc. | Bidding Company | Company | A specialty pharmaceutical company focused on acquiring and commercializing innovative pharmaceuticals. |
| Scott Hirsch | Representative | People | Interim CEO of Endo, involved in the strategic divestiture announcement. |